NZ249346A - 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof - Google Patents

2,6-methano-2h-quinolizine ester derivatives and medicaments thereof

Info

Publication number
NZ249346A
NZ249346A NZ249346A NZ24934693A NZ249346A NZ 249346 A NZ249346 A NZ 249346A NZ 249346 A NZ249346 A NZ 249346A NZ 24934693 A NZ24934693 A NZ 24934693A NZ 249346 A NZ249346 A NZ 249346A
Authority
NZ
New Zealand
Prior art keywords
treatment
compound
release
matrix
pharmaceutically acceptable
Prior art date
Application number
NZ249346A
Other languages
English (en)
Inventor
Maurice Ward Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NZ249346A publication Critical patent/NZ249346A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ249346A 1992-02-24 1993-02-03 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof NZ249346A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24

Publications (1)

Publication Number Publication Date
NZ249346A true NZ249346A (en) 1995-10-26

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ249346A NZ249346A (en) 1992-02-24 1993-02-03 2,6-methano-2h-quinolizine ester derivatives and medicaments thereof

Country Status (14)

Country Link
EP (1) EP0628043A1 (2)
JP (1) JPH07504192A (2)
KR (1) KR100287933B1 (2)
AU (1) AU675060B2 (2)
CA (1) CA2130563C (2)
FI (1) FI105917B (2)
HU (1) HU216831B (2)
IL (1) IL104821A (2)
MX (1) MX9300948A (2)
NO (1) NO943101D0 (2)
NZ (1) NZ249346A (2)
TW (1) TW226374B (2)
WO (1) WO1993017019A1 (2)
ZA (1) ZA931146B (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2672500A (en) 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68924545T2 (de) * 1988-02-23 1996-03-21 Merrell Dow Pharma Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln.
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
EP0628043A1 (en) 1994-12-14
NO943101L (no) 1994-08-23
IL104821A0 (en) 1993-06-10
AU3603493A (en) 1993-09-13
JPH07504192A (ja) 1995-05-11
HU216831B (hu) 1999-09-28
CA2130563C (en) 1997-11-11
ZA931146B (en) 1993-09-14
WO1993017019A1 (en) 1993-09-02
AU675060B2 (en) 1997-01-23
NO943101D0 (no) 1994-08-23
HUT68249A (en) 1995-06-28
FI105917B (fi) 2000-10-31
CA2130563A1 (en) 1993-09-02
TW226374B (2) 1994-07-11
MX9300948A (es) 1993-08-01
KR950700297A (ko) 1995-01-16
FI943872L (fi) 1994-08-23
IL104821A (en) 1997-01-10
FI943872A0 (fi) 1994-08-23
KR100287933B1 (ko) 2001-05-02
HU9402436D0 (en) 1994-10-28

Similar Documents

Publication Publication Date Title
US5011846A (en) Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
JP2657267B2 (ja) ヘキサヒドロ−８−ヒドロキシ−２，６−メタノ−２ｈ−キノリジン−３（４ｈ）−オンのエステル類及び関連化合物類
DE69111816T4 (de) Indolederivate und ihre verwendung als serotonin-antagoniste.
EP0518767B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
IE83573B1 (en) Derivatives of amide analogs of certain methano bridged quinolizines
US5955470A (en) Derivatives of amide analogs of certain methano bridged quinolizines
CA2130563C (en) 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor antagonist
US5508287A (en) 2,6-methano-2H-quinolizin derivative as 5-HT3 -receptor antagonist
EP0507637A2 (en) Use of benzobicyclic carboxamides for the manufacture of a medicament for use as analgesic
EP0329932B1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
CZ286649B6 (cs) 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano-/2,3-e/indol-8-onové deriváty a farmaceutický prostředek s jejich obsahem
US5910501A (en) Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolozin-3(4H)-one and related compounds for treating cognitive disorders
EP0329903A1 (en) Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma
EP0329904A1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
JPH05230057A (ja) 光学活性インダゾール―３―カルボキサミド誘導体及びそれを有効成分とする制吐剤
EP0329905A1 (en) Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: AVENTIS INC., US

Free format text: OLD OWNER(S): MERRELL PHARMACEUTICALS INC.

ASS Change of ownership

Owner name: AVENTISUB II INC., US

Free format text: OLD OWNER(S): AVENTISUB II INC.; AVENTIS INC.

EXPY Patent expired